PMID- 29650271
OWN - NLM
STAT- MEDLINE
DCOM- 20180524
LR  - 20181202
IS  - 1879-0461 (Electronic)
IS  - 1040-8428 (Linking)
VI  - 125
DP  - 2018 May
TI  - Effect of anticoagulants on admission rates and length of hospital stay for acute 
      venous thromboembolism: A systematic review of randomized control trials.
PG  - 12-18
LID - S1040-8428(17)30432-8 [pii]
LID - 10.1016/j.critrevonc.2018.02.010 [doi]
AB  - BACKGROUND: There is a paucity of data available on hospitalization and length of 
      stay (LOS) for different anticoagulant therapies. We sought to compare and 
      summarize admission rates and LOS, and describe the frequency of reporting these 
      two outcomes in randomized control trials (RCTs) comparing different 
      anticoagulant therapies for venous thromboembolism (VTE). METHODS: A literature 
      search was conducted from inception to August 15, 2016 on RCTs of anticoagulant 
      therapy for patients with VTE. Study selection, data extraction and risk of bias 
      analysis were done by two reviewers independently. Meta-analyses were conducted 
      for admission rates and LOS. RESULTS: A total of 4064 articles were identified. 
      There were 74 articles of 70 studies included in the analysis. Hospitalization 
      rates and LOS were reported in 13 (18.6%) and 12 (17.1%) of the 70 included 
      studies, respectively. Low-molecular-weight heparin (LMWH)-treated patients were 
      33.0% less likely to be admitted to hospitals compared to unfractionated heparin 
      (UFH) (RR = 0.67, 95% CI [0.58, 0.78]). The mean difference in LOS between LMWH 
      and UFH was 2.54 days in favor of LMWH (95% CI [-4.94, -0.14]). Compared to 
      parenteral therapy, using rivaroxaban was associated with a lower admission rate 
      for a difference of 1.4-5.1% in VTE, 2.5% in DVT and 0.2% in PE. The LOS of 
      patients receiving rivaroxaban was significant shorter than the LOS in parenteral 
      therapy group for a difference of 1-5 days in VTE, 3 days in DVT and 1 day in PE. 
      CONCLUSION: Admission rates were lower and LOS was shorter using LMWH compared to 
      UFH and oral therapy compared to parenteral therapy for acute VTE treatment in 
      RCTs, based on limited eligible RCTs. These crucial clinically relevant outcomes 
      are underreported in the existing VTE clinical trials.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Hong, Yongzhe
AU  - Hong Y
AD  - Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; The 
      Second Affiliated Hospital of Shantou University Medical College, Shantou, 
      Guangdong, China.
FAU - Mansour, Sola
AU  - Mansour S
AD  - Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
FAU - Alotaibi, Ghazi
AU  - Alotaibi G
AD  - Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; 
      Department of Medicine, King Saud University, Riyadh, Saudi Arabia.
FAU - Wu, Cynthia
AU  - Wu C
AD  - Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
FAU - McMurtry, Michael Sean
AU  - McMurtry MS
AD  - Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. 
      Electronic address: mcmurtry@ualberta.ca.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20180302
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Heparin/therapeutic use
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Length of Stay/*statistics & numerical data
MH  - Patient Admission/*statistics & numerical data
MH  - Pulmonary Embolism/chemically induced/epidemiology/therapy
MH  - Randomized Controlled Trials as Topic/*statistics & numerical data
MH  - Venous Thromboembolism/*chemically induced/*epidemiology/therapy
OTO - NOTNLM
OT  - Admission rates
OT  - Anticoagulants
OT  - Deep vein thrombosis
OT  - Length of stay
OT  - Pulmonary embolism
OT  - Systematic review
OT  - Venous thromboembolism
EDAT- 2018/04/14 06:00
MHDA- 2018/05/25 06:00
CRDT- 2018/04/14 06:00
PHST- 2017/09/14 00:00 [received]
PHST- 2018/01/05 00:00 [revised]
PHST- 2018/02/21 00:00 [accepted]
PHST- 2018/04/14 06:00 [entrez]
PHST- 2018/04/14 06:00 [pubmed]
PHST- 2018/05/25 06:00 [medline]
AID - S1040-8428(17)30432-8 [pii]
AID - 10.1016/j.critrevonc.2018.02.010 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2018 May;125:12-18. doi: 
      10.1016/j.critrevonc.2018.02.010. Epub 2018 Mar 2.